Zobrazeno 1 - 10
of 167
pro vyhledávání: '"G. Posch"'
Autor:
Jovan Veskovic, Mina Cvetkovic, Elvis Tahirovic, Marija Zdravkovic, Svetlana Apostolovic, Dragana Kosevic, Goran Loncar, Danilo Obradovic, Dragan Matic, Aleksandra Ignjatovic, Tatjana Cvetkovic, Maximilian G. Posch, Sara Radenovic, Arsen D. Ristić, Danilo Dokic, Nenad Milošević, Natasa Panic, Hans-Dirk Düngen
Publikováno v:
BMC Cardiovascular Disorders, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Chronic heart failure (CHF) is a severe condition, often co-occurring with depression and anxiety, that strongly affects the quality of life (QoL) in some patients. Conversely, depressive and anxiety symptoms are associated with a
Externí odkaz:
https://doaj.org/article/e898f4781ca242b4ae8e3d6f34552580
Autor:
Lubna Abuqayyas, Laurence E. Cheng, Marcia Teixeira dos Santos, Barbara A. Sullivan, Norma Ruiz‐Santiago, Hui Wang, Yanchen Zhou, Vishala Chindalore, Stanley Cohen, Alan J. Kivitz, Maximilian G. Posch, Jane R. Parnes
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 10, Pp 903-911 (2022)
Objective To assess the safety and biological activity of rozibafusp alfa, a first‐in‐class bispecific antibody–peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid a
Externí odkaz:
https://doaj.org/article/5676c94a2dbb4dc3a8d16a7cdd33da21
Autor:
Maximilian G. Posch, Niklas Walther, Ele Ferrannini, David R. Powell, Phillip Banks, Suman Wason, Raphael Dahmen
OBJECTIVE Inhibiting sodium–glucose cotransporters (SGLTs) improves glycemic and cardiovascular outcomes in patients with type 2 diabetes (T2D). We investigated the differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235ca9e0759259295320417f21733282
https://doi.org/10.2337/figshare.20069063.v1
https://doi.org/10.2337/figshare.20069063.v1
Autor:
Victoria E. R. Parker, Thuong Hoang, Heike Schlichthaar, Fraser W. Gibb, Barbara Wenzel, Maximillian G. Posch, Ludger Rose, Yi‐Ting Chang, Marcella Petrone, Lars Hansen, Philip Ambery, Lutz Jermutus, Hiddo J. L. Heerspink, Rory J. McCrimmon
Publikováno v:
Diabetes, Obesity and Metabolism, 24(7), 1360-1369. Wiley
Aim: To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease.Materials and Methods: In this phase 2a study (NCT03550378), patients with body mass index 25-45 kg/m2, estimated
Autor:
Benjamin A Fisher, Michele Bombardieri, Hans-Ulrich Hockey, Antónia Szántó, Andrew M Wright, Athena Papas, Michael Rotte, Alexandre Avrameas, David A. Isenberg, Bettina Bannert, Pascal Espie, Cyrielle Dupuy, Steven E. Carsons, Diego Kyburz, Maximilian G. Posch, Marie-Anne Valentin, Julie Milojevic, Francesca Barone, Petra M Faerber, Simon J Bowman, Arwa M. Farag, Thomas Daikeler, Xiaohui Ren, Peter Gergely, David Floch, Wan-Fai Ng, James S. Rush, Alan Kivitz
Publikováno v:
The Lancet Rheumatology. 2:e142-e152
Summary Background Primary Sjogren's syndrome is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no systemic therapies for primary Sjogren's syndrome have shown efficacy
Autor:
Juris J. Meier, Tao Wang, Leona Plum-Moerschel, Aidan T Cooper, Philip Ambery, Victoria E R Parker, Darren Robertson, Beate M. Klaus, Tim Heise, Heike Schlichthaar, David C. Hornigold, Marcella Petrone, Boaz Hirshberg, Maximilian G. Posch
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 105:803-820
ContextCotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity.ObjectiveTo evaluate different doses of cotadutide and investigate underlying mechanisms for its glucose-lowering effects.Design/settingRandomize
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of the American Academy of Dermatology. 87(5)
Autor:
Victoria E. Parker, Marcella Petrone, Thuong Hoang, Barbara Wenzel, Heike Schlichthaar, Fraser W. Gibb, Philip Ambery, Hiddo J.L. Heerspink, Rory J. McCrimmon, Maximilian G. Posch, Yi-Ting Chang, Lars Hansen, Lutz Jermutus
Publikováno v:
Diabetes. 70
Background: Cotadutide, a dual glucagon-like peptide (GLP-1) and glucagon receptor agonist, is in development for NASH and T2DM with DKD. GLP-1 receptor agonists have been shown to delay the onset of macroalbuminuria in DKD. The glycemic and renal ef
Autor:
Yue Li, Claudia Simonett, Esther Kamphausen, Louise Mooney, Stephen John Oliver, Maciej Cabanski, Thomas Dörner, Andreas Hüser, Olivier Petricoul, Frank Wagner, Marie-Anne Valentin, Hermann Gram, Julie Milojevic, Maximilian G. Posch
Publikováno v:
Annals of the Rheumatic Diseases. 78:641-647
ObjectivesTo evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s syndrome (pSS) in a double-blind, placebo-controlle